Enhanced anticancer compound may allow precise activation and tracking of treatment

by The Wistar InstituteCredit: The Wistar InstituteResearchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic

Updated on: April 18,2024

Enhanced anticancer compound may allow precise activation and tracking of treatment

by The Wistar InstituteCredit: The Wistar InstituteResearchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic

Updated on:April 18,2024

The protein behind immunotherapy resistance

byEcole Polytechnique Federale de LausanneTumor with FMRP-deficient cancer cells (in green) being infiltrated and attached by killer (CD8) T cells. Credit: Jeremy Guillot (Hanahan Lab – EPFL).Im

Updated on: January 02,2024

The protein behind immunotherapy resistance

byEcole Polytechnique Federale de LausanneTumor with FMRP-deficient cancer cells (in green) being infiltrated and attached by killer (CD8) T cells. Credit: Jeremy Guillot (Hanahan Lab – EPFL).Im

Updated on:January 02,2024

Generating large numbers of universal immune cells could transform cancer immunotherapy

by Agency for Science, Technology and Research (A*STAR), SingaporeA novel method to generate natural killer cells from peripheral blood cell-derived stem cells may transform immunotherapies for d

Updated on: March 12,2024

Generating large numbers of universal immune cells could transform cancer immunotherapy

by Agency for Science, Technology and Research (A*STAR), SingaporeA novel method to generate natural killer cells from peripheral blood cell-derived stem cells may transform immunotherapies for d

Updated on:March 12,2024

Investigating the immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

by Impact Journals LLCMultiple mechanisms underly the pro-tumorigenic role of CD200. Credit: 2023 Shao and Owens.A new research perspective titled "The immunoregulatory protein CD200 as a potenti

Updated on: January 30,2024

Investigating the immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy

by Impact Journals LLCMultiple mechanisms underly the pro-tumorigenic role of CD200. Credit: 2023 Shao and Owens.A new research perspective titled "The immunoregulatory protein CD200 as a potenti

Updated on:January 30,2024

Novel bioassay predicts cancer patients' response to immunotherapy

byBen-Gurion University of the NegevIcAR response to fresh and fixed PDXs and generation of an IcAR score.(A) Schematic representation of the IcAR assay protocol. Following flow cytometry determ

Updated on: January 12,2024

Novel bioassay predicts cancer patients' response to immunotherapy

byBen-Gurion University of the NegevIcAR response to fresh and fixed PDXs and generation of an IcAR score.(A) Schematic representation of the IcAR assay protocol. Following flow cytometry determ

Updated on:January 12,2024

The blind use of AI in health care can lead to invisible discrimination

by University of CopenhagenCredit: CC0 Public DomainArtificial intelligence can help health care systems under pressure allocate limited resources, but also lead to more unequal access. This is d

Updated on: April 22,2024

The blind use of AI in health care can lead to invisible discrimination

by University of CopenhagenCredit: CC0 Public DomainArtificial intelligence can help health care systems under pressure allocate limited resources, but also lead to more unequal access. This is d

Updated on:April 22,2024

Investigational deep learning model may help stratify risk for patients with endometrial cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainAn investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant rec

Updated on: February 03,2024

Investigational deep learning model may help stratify risk for patients with endometrial cancer

by American Association for Cancer ResearchCredit: Pixabay/CC0 Public DomainAn investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant rec

Updated on:February 03,2024

Drug makes tumors more susceptible to chemo

by Massachusetts Institute of TechnologyStructure of the complex containing Rev1 and JH-RE-06. The two copies of the Rev1 protein are shown in dark and light blue, while the small molecule JH-RE-

Updated on: May 25,2024

Drug makes tumors more susceptible to chemo

by Massachusetts Institute of TechnologyStructure of the complex containing Rev1 and JH-RE-06. The two copies of the Rev1 protein are shown in dark and light blue, while the small molecule JH-RE-

Updated on:May 25,2024

Early genome catastrophes can cause non-smoking lung cancer

by The Korea Advanced Institute of Science and Technology (KAIST)Smoking-unrelated oncogenesis of lung cancers by gene fusions. Credit: The Korea Advanced Institute of Science and Technology (KAI

Updated on: April 20,2024

Early genome catastrophes can cause non-smoking lung cancer

by The Korea Advanced Institute of Science and Technology (KAIST)Smoking-unrelated oncogenesis of lung cancers by gene fusions. Credit: The Korea Advanced Institute of Science and Technology (KAI

Updated on:April 20,2024

Two drugs are better than one in fight against leukaemia

by FreshscienceDr Laura Eadie at work in the SAHMRI Leukaemia Research Laboratory. Credit: SAHMRIAdelaide scientists have devised a way to enhance the effectiveness of a patient's leukaemia treatm

Updated on: April 20,2024

Two drugs are better than one in fight against leukaemia

by FreshscienceDr Laura Eadie at work in the SAHMRI Leukaemia Research Laboratory. Credit: SAHMRIAdelaide scientists have devised a way to enhance the effectiveness of a patient's leukaemia treatm

Updated on:April 20,2024

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l

Updated on: January 30,2024

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l

Updated on:January 30,2024

Experts call for a targeted approach to cancer prevention

by University of StirlingCredit: CC0 Public DomainPolicymakers around the world should consider introducing more targeted early interventions in a bid to tackle cancer, according to experts at th

Updated on: April 07,2024

Experts call for a targeted approach to cancer prevention

by University of StirlingCredit: CC0 Public DomainPolicymakers around the world should consider introducing more targeted early interventions in a bid to tackle cancer, according to experts at th

Updated on:April 07,2024